TAGRISSO offers convenient, once-daily dosing, with or without food¹

One 80-mg tablet, orally,
once a day

TAGRISSO tablets may be taken with or without food

TAGRISSO can be dissolved into water and swallowed or taken through an NG tube*

Alternate administration options

If the patient is unable to swallow the tablet, the tablet may first be dispersed in 50 mL of non-carbonated water
- It should be dropped in the water, without crushing, stirred until dispersed and immediately swallowed. An additional half a glass of water should be added to ensure that no residue remains and then immediately swallowed

If administration via nasogastric tube is required, the same process described for diluting in a cup should be followed but using volumes of 15 mL for the initial dispersion and 15 mL for the residue rinses

Target Organ	Adverse reaction*	Recommended dose modification
Pulmonary	ILD/Pneumonitis	Permanently discontinue TAGRISSO
Cardiac	QTc interval greater than 500 msec on at least 2 separate ECGs	Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then restart at a reduced dose (40 mg)
Cardiac	QTc interval prolongation with signs/symptoms of serious arrhythmia	Permanently discontinue TAGRISSO
Other	Grade 3 or higher adverse reaction	Withhold TAGRISSO for up to 3 weeks
	If Grade 3 or higher adverse reaction improves to Grade 0–2 after withholding of TAGRISSO for up to 3 weeks	TAGRISSO may be restarted at the same dose (80 mg) or a lower dose (40 mg)
	Grade 3 or higher adverse reaction that does not improve to Grade 0–2 after withholding for up to 3 weeks	Permanently discontinue TAGRISSO

Reference:
1. AstraZeneca Pharmaceuticals. TAGRISSO^® (osimertinib). Summary of Product Characteristics, 2018.